Literature DB >> 24295830

Molecular mechanisms regulating the synergism between IL-32γ and NOD for the activation of eosinophils.

Chun-Kwok Wong1, Jie Dong, Christopher Wai-Kei Lam.   

Abstract

IL-32 is a proinflammatory cytokine associated with infections, autoimmune diseases, and allergic asthma. In the present study, we elucidated the synergistic effect of IL-32γ and NOD ligand on the activation of human eosinophils, principal effector cells for allergic inflammation, and the underlying mechanisms. Specific IL-32-binding protein, PR3, was found to localize on the cell surface and in the cytoplasm of eosinophils. IL-32γ was more capable of activating eosinophils than its isotype variant IL-32α and exhibited synergistic effect with NOD1 ligand iE-DAP and NOD2 ligand MDP on the induction of allergic inflammation-related IL-1β, TNF-α, and chemokines CXCL8, CCL3, and CCL4 (P<0.05). Moreover, IL-32γ and iE-DAP or MDP induced the significant up-regulation of the cell-surface expression of adhesion molecule CD18 and ICAM-1 on eosinophils. Synergism between IL-32γ and NOD ligands was dependent on the activation of intracellular caspase 1, ERKs, p38 MAPK, and NF-κB pathways in eosinophils. The further-enhanced CD18 and ICAM-1 expression and production of cytokines and chemokines were observed in eosinophils cocultured with human bronchial epithelial BEAS-2B cells. Furthermore, combined treatment of IL-32γ and NOD ligand could activate the release of eosinophil extracellular DNA traps, thereby implying the pathogen-defense mechanisms of eosinophils. Together, the above study provides pivotal immunological mechanisms by which bacterial infection-mediated activation of NOD1,2, together with IL-32γ, can synergize the activation of eosinophils interacting with bronchial epithelial cells.

Entities:  

Keywords:  bronchial epithelial cells; extracellular DNA traps; signal transduction

Mesh:

Substances:

Year:  2013        PMID: 24295830     DOI: 10.1189/jlb.0813452

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  8 in total

1.  IL-32θ gene expression in acute myeloid leukemia suppresses TNF-α production.

Authors:  Man Sub Kim; Jeong-Woo Kang; Jae-Sik Jeon; Jae Kyung Kim; Jong Wan Kim; Jintae Hong; Do-Young Yoon
Journal:  Oncotarget       Date:  2015-12-01

2.  Anti-Allergic Inflammatory Activity of Interleukin-37 Is Mediated by Novel Signaling Cascades in Human Eosinophils.

Authors:  Jing Zhu; Jie Dong; Lu Ji; Peiyong Jiang; Ting Fan Leung; Dehua Liu; Lai Guan Ng; Miranda Sin-Man Tsang; Delong Jiao; Christopher Wai-Kei Lam; Chun-Kwok Wong
Journal:  Front Immunol       Date:  2018-06-22       Impact factor: 7.561

Review 3.  The Biology and Role of Interleukin-32 in Tuberculosis.

Authors:  Wu Li; Wanyan Deng; Jianping Xie
Journal:  J Immunol Res       Date:  2018-10-22       Impact factor: 4.818

Review 4.  Interleukin-32: its role in asthma and potential as a therapeutic agent.

Authors:  Tong Xin; Mo Chen; Liwei Duan; Yanling Xu; Peng Gao
Journal:  Respir Res       Date:  2018-06-25

5.  Eosinophils in anti-neutrophil cytoplasmic antibody associated vasculitis.

Authors:  Thomas Hellmark; Sophie Ohlsson; Åsa Pettersson; Markus Hansson; Åsa C M Johansson
Journal:  BMC Rheumatol       Date:  2019-03-08

6.  Anti-proteinase 3-positive Eosinophilic Granulomatosis with Polyangiitis Revealed by Cardiac Tamponade.

Authors:  Yuji Yamamoto; Yasushi Otani; Fukuko Okabe; Midori Yoneda; Osamu Morimura; Kinya Abe
Journal:  Intern Med       Date:  2019-06-27       Impact factor: 1.271

Review 7.  Immunological Roles of NLR in Allergic Diseases and Its Underlying Mechanisms.

Authors:  Miranda Sin-Man Tsang; Tianheng Hou; Ben Chung-Lap Chan; Chun Kwok Wong
Journal:  Int J Mol Sci       Date:  2021-02-03       Impact factor: 5.923

8.  Role of Carbon Monoxide in Oxidative Stress-Induced Senescence in Human Bronchial Epithelium.

Authors:  Meng-Yun Cai; Chung-Yin Yip; Kewu Pan; Yan Zhang; Renee Wan-Yi Chan; Wood Yee Chan; Wing-Hung Ko
Journal:  Oxid Med Cell Longev       Date:  2022-09-24       Impact factor: 7.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.